Natalizumab treatment during pregnancy - effects on the neonatal immune system

Acta Neurologica Scandinavica

Volumn 127, Issue 1, 2013, Pages

  Schneider, H ^a   Weber, C E ^a   Hellwig, K ^b   Schroten, H ^a   Tenenbaum, T ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

Author keywords

Multiple sclerosis; Natalizumab; Neonate; Outcome; Pregnancy; T cell chemotaxis

Indexed keywords

BETA INTERFERON; CORTICOSTEROID; METHYLPREDNISOLONE; NATALIZUMAB; STROMAL CELL DERIVED FACTOR 1;

ANEMIA; ARTICLE; BLOOD CELL COUNT; BRAIN HEMORRHAGE; BRONCHIOLITIS; CASE REPORT; CELL ISOLATION; CELLULAR DISTRIBUTION; CHEMOTAXIS; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; IMMUNE FUNCTION TEST; IMMUNE SYSTEM; INFANT; MOTHER; MULTIPLE SCLEROSIS; NEWBORN; NEWBORN PERIOD; OUTCOME ASSESSMENT; PREGNANCY; PRENATAL DRUG EXPOSURE; RELAPSE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; THROMBOCYTE COUNT; ULTRASOUND;

ANTIBODIES, MONOCLONAL, HUMANIZED; CASE-CONTROL STUDIES; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNE SYSTEM; INFANT, NEWBORN; INTEGRIN ALPHA4; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; T-LYMPHOCYTES;

EID: 84870854414     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12004     Document Type: Article

References (10)

1. Lenhard T, Biller A, Mueller W, et al. Immune reconstitution inflammatory syndrome after withdrawal of natalizumab? Neurology 2010;75:831-3.
2. Hellwig K, Gold R. Immune reconstitution inflammatory syndrome after withdrawal of natalizumab? Neurology 2011;76:1362-3.
3. Comans-Bitter W, de Groot MR, van den Beemd R, et al. Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations. J Pediatr 1997;130:388-93.
4. Niino M, Bodner C, Simard ML, et al. Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 2006;59:748-54.
5. Bleul CC, Fuhlbrigge RC, Casasnovas JM, et al. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med 1996;184:1101-9.
6. Rispens T, Vennegor A, Wolbink GJ, et al. Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped. Mult Scler 2012;18:899-901.
7. Clifford DB, De Luca A, Simpson DM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010;9:438-46.
8. Kappos L, Bates D, Edan G, et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 2011;10:745-58.
9. Hellwig K, Haghikia A, Gold R. Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler 2011;17:958-63.
10. Wehner NG, Shopp G, Osterburg I, et al. Post-natal development in cynomoglus monkeys following prenatal exposure to natalizumab, an alpha4 integrin inhibitor. Birth Defects Res B Dev Reprod Toxicol 2009;86:144-56.